CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishIL-6 is involved in the pathogenesis of rheumatoid arthritis via its broad effects on immune and inflammatory responses. Our aim was to assess the therapeutic effects of blocking IL-6 by inhibition of the Il-6 receptor with tocilizumab in patients with rheumatoid arthritis. In this double-blind, randomised, placebo-controlled parallel group phase III study, 623 patients were randomly assigned to receive tocilizumab 8 mg/kg (n=205), tocilizumab 4mg/kg (214) or placebo (204) intravenously every 4 week, with methotrexate at stable pre-study doses. The primary endpoint was the proportion of patients with 20% improvement according to ACR criteria at week 24. At 24 weeks, ACR 20 responses were seen in more patients receiving tocilizumab than in those receiving placebo. Tocilizumab could be an effective therapeutic approach in patients with moderate to severe active rheumatoid arthritis.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Data di pubblicazione: | 2008 | |
| Titolo: | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumathoid arthritis (OPTION study): a double blind, placebo controlled, randomized trial. | |
| Autori: | Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos.Remus C; Rovensky J; Alecock E. Woodworth T; Alten R; OPTION investigators ( including Trotta F ). | |
| Rivista: | THE LANCET | |
| Parole Chiave: | Tocilizumab; IL-6; rheumatoid arthritis; clinical trial | |
| Abstract: | IL-6 is involved in the pathogenesis of rheumatoid arthritis via its broad effects on immune and inflammatory responses. Our aim was to assess the therapeutic effects of blocking IL-6 by inhibition of the Il-6 receptor with tocilizumab in patients with rheumatoid arthritis. In this double-blind, randomised, placebo-controlled parallel group phase III study, 623 patients were randomly assigned to receive tocilizumab 8 mg/kg (n=205), tocilizumab 4mg/kg (214) or placebo (204) intravenously every 4 week, with methotrexate at stable pre-study doses. The primary endpoint was the proportion of patients with 20% improvement according to ACR criteria at week 24. At 24 weeks, ACR 20 responses were seen in more patients receiving tocilizumab than in those receiving placebo. Tocilizumab could be an effective therapeutic approach in patients with moderate to severe active rheumatoid arthritis. | |
| Handle: | http://hdl.handle.net/11392/534255 | |
| Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
Copyright © 2022